Skip to main navigation
Menu
  • Focus & Strategy
  • Innovation & Pipeline
  • Disease Areas
  • Investors & Media
  • Contact
Focus & Strategy
  • President’s Letter
  • Leadership
  • Board of Directors
Innovation & Pipeline
  • Roluperidone (MIN-101)
  • Seltorexant (MIN-202)
  • MIN-301
Disease Areas
  • Schizophrenia
  • Insomnia and Mood Disorders
  • Parkinson’s Disease
Investors & Media
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor FAQs
  • Contact Us
Corporate Governance
  • Executive Management
  • Board of Directors
  • Committee Composition
  • Contact the Board
Financials & Filings
  • SEC Filings
  • Annual Reports and Proxies
  • Quarterly Results
  • Key Ratios
Stock Information
  • Historic Stock Lookup
  • Investment Calculator
  • Analyst Coverage
Minerva Neurosciences logo
  • Focus & Strategy
    • President’s Letter
    • Leadership
    • Board of Directors
  • Innovation & Pipeline
    • Roluperidone (MIN-101)
    • Seltorexant (MIN-202)
    • MIN-301
  • Disease Areas
    • Schizophrenia
    • Insomnia and Mood Disorders
    • Parkinson’s Disease
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact Us
  • Contact

INVESTORS & MEDIA

  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor FAQs
  • Contact Us

Shareholder Tools

Printed Materials
Email Alerts
Downloads
RSS
Print
Share

  • RSS

Analyst Coverage

  • Joel Beatty

    Citi
    • Douglas Tsao

      H.C. Wainwright
      • Biren Amin

        Jefferies
        • Jason Butler

          JMP
          • Myles Minter

            William Blair

            Shareholder Tools

            Printed Materials
            Email Alerts
            Downloads
            RSS
            Print
            Share

            • RSS
          • About Us

            • President's Letter
            • Leadership
            • Board of Directors
          • Disease Areas

            • Schizophrenia
            • Insomnia and Mood Disorders
            • Parkinson’s Disease
          • Innovation & Pipeline

            • Roluperidone (MIN-101)
            • Seltorexant (MIN-202)
            • MIN-301
          • (617) 600-7373
            email us
            Privacy Policy | Terms of Use

            Biotech Web Design Company ©2017 Minerva Neurosciences